Novo Nordisk Makes Case For Semaglutide In Pediatric Obesity
The megablockbuster helped 40% of children reduce BMI below the obesity threshold at 68 weeks, compared with 0% for placebo, in the STEP Young trial.
Scrip - September 7, 2026

Supplements Spearhead Prevention Push As Industry Reimagines Consumer Health
Dietary supplements have emerged as industry’s go-to diversification play as manufacturers pivot from treatment to prevention to meet changing consumer preferences. CHPA’s Scott Melville sees a broader convergence of OTCs, supplements, and digital health opening a significant long-term opportunity.
HBW Insight - September 7, 2026

FDA Consumer Health Advisory: Hemp Industry Gets Extra Month To Secure THC Limit Change
What's happening, why it matters and what's next at FDA. This edition covers a one month extension to the deadline which will cut the amount of THC permitted in hemp supplements; a supplement recall following the detection of a pesticide in the product; Kenvue's win after submitting an ad complaint.
HBW Insight - September 7, 2026

Karo Begins APAC Terbinafine Nail Fungus Push In New Zealand
Karo Healthcare's Asia Pacific push to launch Moberg's nail fungus treatment has begun with a New Zealand request to sell 10% terbinafine solution in pharmacies without a prescription.
HBW Insight - September 7, 2026

Deals In Depth: July 2026
Seven $1bn+ alliances were penned in July, and four exceeded $2bn. In the top alliance by deal value, secured $3.4bn in equity capital to improve its capital structure and signed an agreement with asset management firm Apollo.
In Vivo - September 7, 2026

Top 10 Drugs Q2 2026: Mounjaro Pulls $2bn Clear As Keytruda Slips
The second quarter of 2026 showed a reversal from Q1's seasonal softness, with nine of the world's 10 best-selling drugs posting sequential gains. The top-10 aggregate reached $54,948m, up 12.7% quarter-on-quarter and 25.3% year-on-year.
Scrip - September 7, 2026

Regulating AI In Regulatory Affairs: How Legislation Is Changing Governance
In an exclusive interview, Columbus’ Tarn Brown discusses how the EU AI Act puts a new onus on pharma and medtech companies to improve training, literacy and oversight for AI in regulatory affairs.
In Vivo - September 7, 2026

Finance Watch: Few VC Mega-Rounds, But Summer Brings Several Smaller Deals
The pace of $100m-plus venture capital mega-rounds noticeably slowed in August, but AusperBio revealed a $120m series C round at the end of the month. Also, Superluminal raised $60m and Typewriter emerged with $56m, among other smaller VC deals.
Scrip - September 7, 2026

Cipla Joins The US Keytruda Biosimilar Line Up With Qilu Alliance
Cipla secures US commercial rights to Qilu Pharmaceutical's QL2107 pembrolizumab candidate, marking another step in the firm’s biosimilar pivot.
Generics Bulletin - September 7, 2026

Celltrion Gets Further Trial Nods For Keytruda And Darzalex Biosimilars
Celltrion has received nods for amended Phase III trial plans for its CT-P51 and CT-P44 proposed biosimilars to Keytruda (pembrolizumab) and Darzalex (daratumumab) from regulators in the US and Korea.
Generics Bulletin - September 7, 2026

Cepheid’s Ebola Test Becomes Fourth WHO Emergency Diagnostic
One hundred days into the Bundibugyo virus outbreak, rapid diagnostics have seen strong progress, but true point-of-care tests remain elusive.
Medtech Insight - September 7, 2026

Pipeline Watch: Two Approvals And Ten Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - September 7, 2026

Renexxion’s Pipeline-In-A-Pill Ambitions Face Their First Test In Gastroparesis
The co-founder of privately held biotech Renexxion tells Scrip why naronapride can succeed in gastroparesis where a generation of prokinetics failed.
Scrip - September 7, 2026

Formosa Files European Trial Application For Roche’s Kadcyla Biosimilar
With Kadcyla biosimilar rivals still thin on the ground, Formosa Pharmaceuticals has filed a European clinical trial application for its co-developed biosimilar TSY-110.
Generics Bulletin - September 7, 2026

Aspen Raises Sterile Ambitions As Reshape Delivers Ahead Of Plan
Aspen has lifted its FY2027 Sterile FDF recovery target after a restructuring delivered ahead of plan, with returning volumes and a leaner cost base set to make the business the group’s main profit growth driver.
Generics Bulletin - September 7, 2026

Carvolix Will Accelerate AI/Robotic Cardio And Stroke Plans With €30m Debt Funding
Euronext-listed French cardiac and stroke device innovator Carvolix is doubling down on progressing its five-product portfolio armed with a new milestone-based €30m package of debt funding from Claret Capital.
Medtech Insight - September 7, 2026

Novo Nordisk Stops Two More Studies As IL-6 Drug Falls Short
Another blow for Novo after data monitoring committee sees little hope of success for ziltivekimab in two further trials.
Scrip - September 7, 2026

MHRA Could Gain Expanded Device Licensing Authority As UK Considers New Regulatory Framework
In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to eventually replace approved bodies.
HBW Insight - September 7, 2026

FDA Backs PFAS In Medical Devices As Europe Moves To Ban Them And Suppliers Offer Alternatives
FDA reaffirms fluoropolymers such as PTFE are safe and irreplaceable in devices, but the reprieve is US-only: an EU REACH restriction, tighter EPA reporting and supplier exits are already pushing device makers toward PFAS-free alternatives.
Medtech Insight - September 7, 2026

Claret Capital Fund IV: €575m European Growth Lending Closes With Life Sciences Focus
Growth-stage and start-up companies in medical devices and life sciences are looking at debt growth capital with new eyes. A just-closed €575m European growth lending fund from Claret Capital Partners will meet some of the rising demand, says Joey Mason, life sciences venture partner at the firm.
In Vivo - September 7, 2026